Dr. Nicole Gordon

Claim this profile

AIS Cancer Center at San Joaquin Community Hospital

Studies Breast Cancer
Studies Breast cancer
3 reported clinical trials
8 drugs studied

Area of expertise

1Breast Cancer
Nicole Gordon has run 3 trials for Breast Cancer. Some of their research focus areas include:
ER positive
PR positive
HER2 negative
2Breast Cancer
Nicole Gordon has run 2 trials for Breast cancer. Some of their research focus areas include:
ER positive
PR positive
HER2 negative

Affiliated Hospitals

Image of trial facility.
AIS Cancer Center At San Joaquin Community Hospital
Image of trial facility.
Adventist Health Bakersfield

Clinical Trials Nicole Gordon is currently running

Image of trial facility.

Genomic Testing

for Breast Cancer

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Recruiting1 award N/A3 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

More about Nicole Gordon

Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Nicole Gordon has experience with
  • Hormone Therapy
  • Cyclophosphamide
  • Doxorubicin
  • Durvalumab
  • Paclitaxel
  • BluePrint

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Nicole Gordon specialize in?
Is Nicole Gordon currently recruiting for clinical trials?
Are there any treatments that Nicole Gordon has studied deeply?
What is the best way to schedule an appointment with Nicole Gordon?
What is the office address of Nicole Gordon?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security